
- Eisai’s operating income for the third quarter was 27.57 billion yen, significantly surpassing the estimated 10.75 billion yen.
- The company’s net income reached 23.79 billion yen, well above the forecasted 8.22 billion yen.
- Net sales for the period amounted to 216.14 billion yen, exceeding the expectation of 188.87 billion yen.
- For the full year, Eisai maintains its forecast for operating income at 53.50 billion yen, slightly under the estimate of 56.3 billion yen.
- The projected net income for the year is 43.00 billion yen, compared to an estimate of 45.42 billion yen.
- Annual net sales are expected to be 754.00 billion yen, marginally lower than the estimated 766.95 billion yen.
- The company continues to project an annual dividend of 160.00 yen, matching market estimates.
- Analyst recommendations include 6 buys, 8 holds, and 2 sells.
“`
Eisai Co Ltd on Smartkarma
Analyst coverage of Eisai Co Ltd on Smartkarma reveals a mixed bag for the pharmaceutical company in H1FY25. According to Tina Banerjee‘s report, Eisai experienced a 3% year-on-year revenue growth driven by mainstay drugs. However, operating profit saw an 11% decline and net profit decreased by 6% during the same period. The company reaffirmed its total revenue guidance for FY25 but reduced the revenue guidance for Leqembi by Β₯14B to Β₯42.5B due to lower expectations from the Americas. Leqembi, a key product, is expected to face competition in the U.S. market next year despite potential approval in Europe for a narrower patient base.
Tina Banerjee‘s analysis on Smartkarma indicates a bearish sentiment towards Eisai Co Ltd, emphasizing the challenges faced by the Leqembi product line. The struggle for Leqembi continues as the company grapples with declining profits and adjusts revenue forecasts for the upcoming fiscal year. Despite the revenue growth in H1FY25 driven by core drugs, the overall performance reflects a more cautious outlook for Eisai. The report highlights the impact of market dynamics on the company’s financial health, pointing towards a challenging road ahead for Eisai in navigating the competitive pharmaceutical landscape.
A look at Eisai Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores analysis, Eisai Co Ltd has a promising long-term outlook. With a strong dividend score of 4, the company demonstrates a commitment to rewarding its shareholders. Additionally, a value score of 3 indicates that the company’s stock may offer good value for investors. However, the growth and momentum scores of 2 each suggest that Eisai Co Ltd may face challenges in terms of expanding its business and maintaining a steady upward trajectory in the market.
Furthermore, the company’s resilience score of 3 reflects its ability to withstand economic downturns and market fluctuations. Overall, Eisai Co Ltd‘s diversified portfolio of prescription drugs, medical equipment, and other products positions it well for continued growth and stability in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars